To study how benefits are distributed, we stratify people by age at treatment initiation and by risk assessed one of two ways: BMI at time of treatment initiation
During the Pharmaceutical Online live panel Analytical Strategies for High-Volume GLP-1 Manufacturing, Matteo Villain, Vice President of Peptide & Oligonucleotide Strategic Initiatives at Veranova, and Leonardo Costa Siqueira, U.S
We found that treatment significantly increased the plasma concentration of glycine and enhanced the urinary excretion of isobutyrylglycine, tigylglycine, isovalerylglycine, and hexanoylglycine
10.1016/j.pharmthera.2022.108165 Pharmacol Ther
Otros efectos descritos incluyen reacciones en el lugar de la inyeccin, cefalea, fatiga, estreimiento, reflujo gastroesofgico, alopecia e hipoglucemias (menos frecuentes en no diabticos)